Spun off from Novartis in 2019, Alcon is betting on new product launches to accelerate sales growth in the second half of ...

Alcon, a global eye care company known for products such as Systane and GenTeal Tears, plans to launch Tryptyr in the U.S.

The FDA has approved Tryptyr (acoltremon) as the first TRPM8-targeting eye drop for dry eye disease, stimulating natural tear ...

Learn which drugs can cause dry eye disease, and what to do if you’re taking a medication that can cause dry eye symptoms.

The active ingredient in Tryptyr is acoltremon, an agonist of transient receptor potential melastatin 8 thermoreceptors.

It's as if she's squinting through a smoke-filled room. But it's Charisse Brown's eye condition, glaucoma, that diminishes her vision. Brown, 38, has worked all her adult life, with a personal policy ...

Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms ...

Six years after being spun out from Novartis and becoming a public company, eye care specialist Alcon has gained its first ...

The FDA cleared an investigational new drug application for a phase 2 trial of GRF312 ophthalmic solution, an immunoglobulin ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Selagine, Inc., a spin-out company from the University of Illinois Chicago (UIC), announced today that the U.S. Food and Drug ...

A new randomized controlled trial reveals that topical timolol significantly improves the appearance of post-mammoplasty ...